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Abstract 
Objective: To study the effect of octreotide on colonic motility in pediatric patients with 
recalcitrant chronic constipation/encopresis and other suspected colonic motility 
disorders. 
Methods: This was a non-randomized, single center, open label, prospective study 
evaluating the effect of a single subcutaneous dose of octreotide on colonic motility 
Results: Thirteen patients (5 male) were enrolled in the study. The age range was 4.6-
16.2 years. Eleven patients (84%) had normal colonic manometry and two patients (16%) 
had colonic neuropathy. Motility Index (MI) (mm Hg) for the 15 minutes before and after 
octreotide infusion was 6.03 ± 1.26 (95% CI, 5.35-6.72), and 5.32 ± 1.66 (95% CI, 4.42-
6.23) respectively with p-value of 0.08. MI for the 30 minutes before and after octreotide 
infusion was 6.89 ± 1.37 (95% CI, 6.14-7.64) and 6.71 ± 1.47 (95% CI, 5.91-7.52) 
respectively with p-value of 0.55. MI for the 45 minutes before and after octreotide 
infusion was 7.73 ± 1.32 (95% CI, 7.01-8.45) and 7.53 ± 1.38 (95% CI, 6.78-8.28) 
respectively with p-value of 0.8. 
Conclusion: Our study showed that administration of octreotide resulted in no significant 
changes in colonic motility index in pediatric patients with chronic recalcitrant 
constipation. 
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What is Known/What is New:  
 Treatments options for patient with intractable constipation and colonic
dysmotility are very limited.
 Octreotide induces phase III of the migrating motor complex in the small 
intestine. Octreotide causes no significant changes in colonic motility index in 
pediatric patients with chronic recalcitrant constipation with normal colonic 
manometry. 
 
Introduction  
Constipation is a common problem worldwide with an estimated prevalence of 
3%.1 In the Western world 10-20% of adults have constipation.2 Constipation is commonly 
encountered in pediatrics as well, contributing to 3% of general pediatrician office visits 
and 25% of pediatric gastroenterology visits.3 Bongers et al studied the long-term prognosis 
of pediatric patients with constipation; nearly 30% of patients continued to be symptomatic 
despite aggressive medical and behavioral therapy, with a mean follow up of 11 years.4 
These subsets of patients with intractable constipation often need a colonic motility study 
to determine if their symptoms are due to a colonic dysmotility.5 Based on the results of 
the study, appropriate therapeutic interventions may be recommended. Patients with 
intractable constipation and normal colonic motility are often offered surgical treatment 
(MACE/cecostomy) if all medical therapy has failed.6 Patients with true dysmotility may 
need MACE/cecostomy or total or segmental colonic resection depending on severity of 
colonic dysmotility. There is a need to identify newer medical therapies to treat patients 
with intractable constipation and colonic dysmotility as treatments options are very 
limited.5  
Octreotide is a synthetic octapeptide analog of somatostatin.7 It has several 
gastrointestinal actions.8-11 Octreotide induces phase III of the migrating motor complex in 
the small intestine.12 Von der Ohe et al conducted a randomized blind study assessing the 
regional effects of octreotide on the gastrointestinal tract; the study showed improvement 
in the colonic motility index and statistically significant phasic pressure activity in the 
octreotide group compared to placebo.13 Soudah et al showed that octreotide stimulated 
rectosigmoid motility via cholinergic pathways resulting in improved colonic transit.14 
Scarpignato et al used octreotide in small pulse doses in patients with irritable bowel 
syndrome and noticed that it accelerated intestinal transit.15 Cullen et al used octreotide in 
postoperative ileus and showed that octreotide has a dose dependent action on colonic 
motility; used in low doses it acted as a prokinetic agent and resulted in patients having a 
bowel movement earlier.16 
We have used octreotide during colonic motility studies in seven patients who had 
no response to a standard dose of bisacodyl. All seven patients had high amplitude 
propagated colonic contractions (HAPC) within 5-10 minutes of administration of 
octreotide and tolerated the medication well.17 However, there might have been a 
confounding factor, given that all patients received bisacodyl prior to octreotide.   
The aim of this pilot study was to investigate the effect of octreotide on colonic 
motility in pediatric patients with recalcitrant chronic constipation/encopresis and other 
suspected colonic motility disorders.   
 
Materials and Methods 
This was a non-randomized, single center, open label, and prospective study.  The 
study was approved by the institutional review board of Indiana University after 
obtaining an Investigational New Drug (IND) application from the Food and Drug 
Administration (FDA). This study was registered at clinical trials and trial identification 
number is NCT01917773.  
For inclusion criterion any child between one to eighteen years of age who was 
undergoing a colonic motility study at Riley Hospital for Children was eligible to 
participate in the study. The exclusion criteria were: 1) subjects with known or suspected 
allergy to octreotide, 2) subjects with known prolonged QTc Syndrome or highest risk 
QTc-Prolonging Agents (including mifepristone), 3) subjects with known history of 
ventricular arrhythmia, 4) subjects with history of organ transplant taking cyclosporine at 
the time of the motility study, 5) subjects with history of small bowel transplant, 6) 
subjects less than one year or older than eighteen years of age, 7) subjects with severe 
renal impairment, 8) subjects with severe hepatic impairment, 9) subjects taking 
bromocriptine, insulin, oral hypoglycemic agents, beta blockers, calcium channel 
blockers, quinidine, terfenadine, pimozide, sildenafil, tadalafil, and any agents to control 
fluid and electrolyte imbalance.  
 
All eligible patients referred for colonic manometry to the Gastrointestinal Motility 
Laboratory at Riley Hospital for Children between September 2013 and June 2014 were 
invited to participate in the study.   Informed consent was obtained from parents/legal 
guardian of each enrolled child and assent was obtained from all patients older than 7 years.   
 
Protocol of Colonic Manometry 
Laxatives were discontinued 48 hours before colonic manometry. A standard 
bowel preparation (oral or nasogastric infusion of polyethylene glycol/electrolyte) was 
prescribed the day before colonoscopy for motility catheter placement. On the day of the 
motility catheter placement colonoscopy was performed, and a motility catheter was 
placed under direct visualization. Colonoscopy was performed under standardized 
general anesthesia protocol consisting of premedication with midazolam and induction 
and maintenance of anesthesia using sevoflurane. The motility catheter was grasped by a 
polypectomy snare and was advanced to the most proximal point in the colon that was 
accessible. A plain abdominal x-ray was ordered within two to three hours after 
completion of the procedure and again in the middle of the colonic motility study to 
document the approximate location of the pressure ports on the catheter.  
 
The protocol for manometry was as follows. 
1. Fasting motility was recorded for at least 60 minutes. 
2. Octreotide 1mcg/kg, maximum of 50mcg was administered subcutaneously (one 
hour after application of EMLA topical cream). Motility was then recorded for 
45-60 minutes. 
3. Patients were then offered a high-fat, high-energy meal as described elsewhere, 
and motility was recorded for 60 minutes.18 
4. Patients then received 1 to 2 doses of bisacodyl (0.2 mg/kg, maximum of 10 mg) 
through the motility catheter, and motility was recorded.19  
 
Data and Statistical Analysis:  
Colonic motility was measured using a solid-state catheter. The catheter had 36 
sensors spaced 5cm apart for the first 15 sensors and 1cm apart for the remaining sensors. 
Pressures were transmitted to a transducer and recorded on a personal computer system 
(Medical Measurement Systems USA, Inc.). Manometry tracings were visually analyzed 
for the presence of high-amplitude propagating contractions (HAPCs), defined as 
contractions of at least 60 mm Hg in amplitude, 10 seconds in duration, and propagating 
for at least 30 cm of the colon. Normal manometry was defined as the presence of at least 
one HAPC originating in the proximal colon and propagating to the sigmoid colon.20 
Neuropathy was defined as the persistent presence of a pattern of low- or high-amplitude 
contractions that were non-propagating (retrograde or simultaneous). Myopathy was 
defined as complete absence of contractions or persistence of a pattern of contractions 
with normal propagation but abnormally low amplitude in a non-dilated colon. Motility 
index (MI) was calculated using the Medical Measurement Systems (MMS) computer 
program. The MI represents the area under the curve of the pressure tracing for a certain 
period.21 The MI was calculated for each channel. The MIs from all channels were then 
averaged to give each patient one average MI for the particular period under study. In this 
study, MI was calculated for the periods of 15, 30, and 45 minutes before and after 
infusion of octreotide. Motility index is reported as millimeters of mercury (mm Hg) per 
15, 30 or 45 minutes. 
There are no commonly accepted norms for colonic motility index in children 
using the solid-state colonic motility catheter technique. Reported MIs and SDs in 
healthy volunteers from an adult study were used to calculate sample size.22 A sample 
size of 13 patients was deemed adequate to detect a 25% change in MI with 80% power. 
The Wilcoxon signed rank test was used to analyze change in MI. Values were 
considered to be significant if P <0.05. 
 
 
Results 
Demographics: 
Twenty-four patients were assessed for eligibility to participate in the study. Eight 
patients were excluded, as they did not meet inclusion criteria. Three patients/parents 
refused to be part of the study. Thirteen patients were enrolled in the study. The age range 
was 4.6-16.2 years with a mean age of 9.3 ± 3.3 years. Seven patients were male and six 
patients were female. Twelve patients were white and one patient was black. Indications 
for colonic manometry included refractory constipation with encopresis (11), constipation 
without encopresis (1) and constipation post pull-through procedure for Hirschsprung’s 
disease (1). Seventy seven percent of patients had significant comorbidities (Table 1). 
Eleven patients had undergone anorectal manometry (ARM) and results showed presence 
of recto-anal inhibitory reflex and normal defecation dynamics (5), presence of RAIR 
with paradoxical contraction during simulated defecation (3), absent RAIR and normal 
rectal biopsy (2), and absent RAIR post Hirschsprung's disease (HD) surgery  (1) (Table 
1).    All three patients with positive RAIR with paradoxical contraction during simulated 
defecation had failed biofeedback therapy. Six patients had undergone rectal biopsy and 
ganglion cells were present in five patients (one was diagnosed with Hirschsprung’s 
disease).  
A motility catheter was placed via colonoscopy in all 13 patients. The catheter 
was advanced to the cecum in 7 patients, ascending colon in 3 and hepatic flexure in 3. 
Six patients complained of mild discomfort with administration of subcutaneous 
octreotide but did not require any analgesic, as discomfort was short lived. Three patients 
complained of mild abdominal cramping. None of the patients developed hypoglycemia.    
 
Qualitative analysis of effect of Octreotide:   
Eleven patients had normal manometry. Two patients had colonic neuropathy. Of 
the 11 healthy patients, none had fasting HAPCs, one had post-octreotide HAPCs, two 
had postprandial HAPCs, and all had post bisacodyl HAPCs. Octreotide failed to produce 
any noticeable visual changes in the manometry pattern compared to the fasting period in 
all but two patients. 
 
Quantitative analysis of effect of Octreotide: 
Average MI for all patients was calculated over 15-minutes, 30-minutes and 45-
minutes before and after administration of octreotide.  The MI for the 15 minutes before 
and after octreotide infusion was 6.03 ± 1.26 mm Hg/15 min (95% confidence interval, 
5.35-6.72), and 5.32 ± 1.66 mm Hg/15 min (95% confidence interval, 4.42-6.23) and p-
value was P=0.087. The MI for the 30 minutes before and after octreotide infusion was 
6.89 ± 1.37 mm Hg/30 min (95% confidence interval, 6.14-7.64) and 6.71 ± 1.47 mm 
Hg/30 min (95% confidence interval, 5.91-7.52) and p-value was P=0.552. MI for the 45 
minutes before and after octreotide infusion was 7.73 ± 1.32 mm Hg/45 min (95% 
confidence interval, 7.01-8.45) and 7.53 ± 1.38 mm Hg/45 min (95% confidence interval, 
6.78-8.28) and p-value was P=0.807. Motility index increased in three, six and seven 
patients at 15, 30 and 45 minutes after administration of octreotide, respectively (Figure. 
1).  However, overall motility index decreased post octreotide during each time period. 
Only in one patient MI increased more than 25% from baseline following administration 
of octreotide (patient 11).  
A sub analysis of 11 patients with normal colonic manometry showed no 
significant changes in MI 15 minutes, 30 minutes and 45 minutes after octreotide 
administration. The MI for the 15 minutes before and after octreotide was 5.99 mm 
Hg/15 min and 5.27 mm Hg/15 min (p-value 0.075) respectively. The MI for the 30 
minutes before and after octreotide was 6.84 mm Hg/30 min and 6.64 mm Hg/30 min (p-
value 0.534) respectively. The MI for the 45 minutes before and after octreotide was 7.66 
mm Hg/45 min and 7.5 mm Hg/45 min (p-value 0.86) respectively. 
A secondary analysis on all 13 patients post bisacodyl infusion showed no 
significant changes. The average 15 minutes MI post-bisacodyl was 6.7 mm Hg 
compared to pre-bisacodyl MI of 6.03 2 mm Hg (p-value 0.249). Reanalysis of the 11 
patients with normal colonic manometry alone showed significant changes post bisacodyl 
infusion as expected. The average 15 minutes MI post-bisacodyl was 7.2 mm Hg 
compared to pre-bisacodyl MI of 5.992 mm Hg (p-value 0.049). 
 
Discussion 
Octreotide is a synthetic octapeptide analogue of somatostatin. Octreotide is used 
to treat several pediatric disorders including secretory diarrhea, gastrointestinal 
hemorrhage, dumping syndrome, gastrointestinal fistula and pseudo obstruction.11 
Octreotide has been shown to have several actions on the colon including increased 
phasic pressure activity, and increased transit time.13-16 We chose to use the dose of 
1mcg/kg with a maximum of 50mcg based on reports in the literature.23 A similar 1 
mcg/kg dose has been used during antroduodenal motility studies in pediatric patients to 
induce phase III of the migrating motor complex.  Di Lorenzo et al reported using this 
dose in their prospective study of pediatric patients undergoing antroduodenal motility 
studies without any adverse effects.12 Also, octreotide is used for gastrointestinal 
bleeding where 1 mcg/kg is given as a bolus intravenous dose, followed by 1 mcg/kg/hr 
for 48 hours.24 We used sevoflurane anesthesia protocol as we have shown previously 
that anesthesia protocol does not alter colonic motility study findings.25 
In our study octreotide was overall well tolerated. Six patients had mild 
discomfort with administration of subcutaneous octreotide. Three patients had mild 
abdominal discomfort.  
In this study, the effects of a single subcutaneous dose of octreotide on colonic 
motility was evaluated in pediatric patients with chronic recalcitrant constipation. The 
study shows that octreotide did not increase colonic MI. In fact in the first 15 minutes 
post octreotide the MI decreased. Octreotide induced HAPC’s in only one patient. Based 
on this observation we conclude that octreotide is unlikely to benefit patients with 
chronic intractable or recalcitrant constipation.  
We have used octreotide previously in patients who had no HAPC’s after bisacodyl 
infusion during a colonic motility study. Octreotide induced HAPC’s within 5-10 minutes 
in most of these patients.17When we compare this study result to our previous experience, 
it appears that octreotide may augment bisacodyl’s effects but is not able to induce HAPC’s 
on its own.   
Our study has a few limitations. We did not have a healthy control group; 
however, it will be difficult to enroll healthy controls and expose them to an invasive and 
expensive procedure. The study was an open-label design and not a randomized double 
blind control study; however, the risk of bias is minimal as we are studying an objective 
data, i.e., colonic MI, which is computer generated. As we had only two patients with 
colonic neuropathy, it is difficult to conclude effect of octreotide in colonic neuropathy 
patients.  
In conclusion our study shows that administration of octreotide resulted in no 
significant changes in colonic motility index in pediatric patients with chronic recalcitrant 
constipation with normal colonic manometry study. Additional studied are needed to assess 
response of octreotide in patients with colonic neuropathy and myopathy.  We previously 
have shown that octreotide induced HAPC’s in patients who had no response to a standard 
dose of bisacodyl. This observation suggests that octreotide likely enhances the effect of 
bisacodyl. However further research is needed to confirm this hypothesis. 
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